Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;64(1):14-30.
doi: 10.1007/s12020-019-01895-z. Epub 2019 Mar 14.

Novel PET tracers: added value for endocrine disorders

Sébastien Bergeret  1 , Judith Charbit  1 , Catherine Ansquer  2   3 , Géraldine Bera  1   4 , Philippe Chanson  5   6 , Charlotte Lussey-Lepoutre  7   8
Affiliations
Review

Novel PET tracers: added value for endocrine disorders

Sébastien Bergeret et al. Endocrine. 2019 Apr.

Abstract

Nuclear medicine has been implicated in the diagnosis and treatment of endocrine disorders for several decades. With recent development of PET tracers, functional imaging now plays a major role in endocrine tumors enabling with high performance to their localization, characterization, and staging. Besides 18F-FDG, which may be used in the management and follow-up of endocrine tumors, new tracers have emerged, such as 18F-DOPA for neuroendocrine tumors (NETs) (medullary thyroid carcinoma, pheochromocytomas and paragangliomas and well-differentiated NETs originating from the midgut) and 18F-Choline in the field of primary hyperparathyroidism. Moreover, some peptides such as somatostatin analogs can also be used for peptide receptor radionuclide therapy. In this context, Gallium-68 labeled somatostatin analogs (68Ga-SSA) can help to tailor therapeutic choices and follow the response to treatment in the so-called "theranostic" approach. This review emphasizes the usefulness of these three novel PET tracers (18F-Choline, 18F-FDOPA, and 68Ga-SSA) for primary hyperparathyroidism and neuroendocrine tumors.

Keywords: 18F-Choline; 18F-FDG; 18F-FDOPA; Gallium-68; Neuroendocrine tumors; PET/CT; Primary hyperparathyroidism; Somatostatin.

PubMed Disclaimer

References

    1. Eur J Nucl Med. 2001 Jan;28(1):64-71 - PubMed
    1. Medicine (Baltimore). 2015 Oct;94(41):e1701 - PubMed
    1. Nucl Med Commun. 2009 Apr;30(4):281-6 - PubMed
    1. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):943-66 - PubMed
    1. J Nucl Med. 2016 Feb;57(2):186-91 - PubMed

MeSH terms

LinkOut - more resources